We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01972867
Recruitment Status : Active, not recruiting
First Posted : October 31, 2013
Last Update Posted : June 21, 2022
Information provided by (Responsible Party):
Angiodynamics, Inc.

Brief Summary:
The purpose of this study is to evaluate the feasibility and short-term safety and effectiveness of the NanoKnife System when used to ablate localized prostate cancer in intermediate risk subjects with organ-confined prostate cancer. This study will evaluate the feasibility of the NanoKnife System as a focal therapy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Device: NanoKnife Procedure Not Applicable

Detailed Description:
This study will involve six (6) subjects who meet the intermediate risk prostate cancer criteria defined by this protocol. The biopsy and imaging techniques that we will adopt within this trial are multiparametric MRI (mpMRI) and transperineal prostate biopsy (template mapping and/or limited targeted). The subjects' prostate cancer foci, the location of which will be determined by ultrasound guided transperineal prostate biopsy, will be targeted for treatment with the NanoKnife System. The primary objective of this the study will be to evaluate procedural and short-term post treatment safety of the NanoKnife treatment via incidence of adverse events and evaluation of effect on urologic (urinary and erectile) function. The secondary objective of this study is to evaluate the short term efficacy of the NanoKnife treatment. Local efficacy in the area of treatment will be assessed by histological evaluation of transperineal prostate biopsy cores at six (6) months post NanoKnife treatment, to evaluate the ablation zone created by the NanoKnife treatment. Other secondary outcomes include health-related quality of life levels evaluated using validated patient questionnaires. Following the 6 month transperineal prostate biopsy and mpMRI assessment, the data from these 6 subjects will be submitted to FDA for confirmation of short term safety and efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in an Intermediate Risk Patient Population
Actual Study Start Date : May 13, 2021
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: NanoKnife Procedure
The NanoKnife procedure will be performed on focal prostate tumors, under ultrasound guidance.
Device: NanoKnife Procedure
Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.
Other Name: NanoKnife

Primary Outcome Measures :
  1. Treatment procedural and short-term post-treatment safety profile [ Time Frame: 6 months ]
    To determine the NanoKnife treatment procedural and short-term post-treatment safety profile by evaluating adverse event incidence, type, duration, severity and relationship to study device.

  2. Treatment Morbidity Profile [ Time Frame: 6 months ]
    To determine the NanoKnife treatment morbidity profile by evaluating urinary and erectile function.

Secondary Outcome Measures :
  1. Completeness of Ablation [ Time Frame: 6 months ]

    To determine completeness of ablation in the targeted prostate cancer tissue, in relation to probe placement and treatment parameters applied, as determined by histological evaluation of transperineal prostate biopsy cores at six (6) months post- treatment.

    • Determine post-treatment PSA kinetics
    • Determine effectiveness of therapy by post-treatment imaging (necrosis, presence of residual tissue)
    • Determine effectiveness of therapy by rates of biochemical and clinical progression; need for secondary or adjuvant treatment

  2. Prostate-Specific Antigen Kinetics [ Time Frame: 24 months ]
    Determine post-NanoKnife treatment prostate-specific antigen (PSA) kinetics including time to PSA nadir and post-nadir PSA stability.

  3. Effectiveness of Therapy [ Time Frame: 24 months ]
    To determine the effectiveness of therapy by post-treatment early-contrast MRI and multiparametric magnetic resonance imaging (mpMRI) to evaluate the area of necrosis and presence of residual tissue.

  4. Effectiveness of Therapy [ Time Frame: 24 months ]
    To determine the effectiveness of therapy by recording the rates of biochemical and clinical progression and the need for secondary or adjuvant treatment following therapy.

  5. Health-Related Quality of Life [ Time Frame: 24 months ]
    To determine health-related quality of life (HRQoL) levelsafter NanoKnife using validated patient questionnaires.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Has at least a 10-year life expectancy
  2. Have histologically confirmed organ-confined prostate cancer - clinical Stage ≤ T2c
  3. Have a PSA ≤ 15 ng/mL or PSA density < 0.15 ng/mL2 if PSA is > 15 ng/mL
  4. Has Gleason score 3+4 or 4+3
  5. Has 10 mm or less of cancer-bearing prostate tissue in any biopsy core
  6. No evidence of extraprostatic extension or seminal vesicle invasion by mpMRI
  7. Able to visualize prostate gland adequately on transrectal ultrasound imaging during enrollment evaluation
  8. Transperineal targeted prostate biopsies of lesion, plus 12 core systematic biopsies to include adequate sampling of the peripheral zone correlating with an intermediate risk lesion in the area of the MR-visible lesion.
  9. A visible lesion on mpMRI that is accessible to Irreversible Electroporation (IRE) treatment
  10. A non-MRI visible lesion detected via systematic standard biopsy will not be considered an exclusion condition provided the non-MRI visible lesion is singularly located in the contralateral hemisphere of the prostate; is Gleason 6; and comprises no more than 6mm linear extent of cancer-bearing tissue in a single core on standard biopsy.
  11. Must sign a written informed consent
  12. Understands and accepts the obligation and is logistically able to present for all scheduled follow-up visits

Exclusion Criteria:

  1. Have known hypersensitivity to pancuronium bromide, atricurium or cisatricurium
  2. Unfit for anesthesia or have a contraindication for agents listed for paralysis
  3. Have an active urinary tract infection (UTI)
  4. Have a history of bladder neck contracture
  5. Are interested in future fertility
  6. Have a history (within 3 years) of inflammatory bowel disease
  7. Have a concurrent major debilitating illness
  8. Had a malignancy within 5 years, including malignant melanoma, except for prostate cancer or other types of skin cancer
  9. Have any active implanted electronic device (e.g., pacemaker)
  10. Are unable to catheterize due to a urethral stricture disease
  11. Have had prior or current prostate cancer therapies:

    1. Biologic therapy for prostate cancer
    2. Chemotherapy for prostate cancer
    3. Hormonal therapy for prostate cancer within three months of procedure
    4. Radiotherapy for prostate cancer
    5. Surgery for prostate cancer
  12. Have had prior transurethral prostatectomy (TURP), stricture surgery, urethral stent or prostatic implants
  13. Have had prior major rectal surgery (except hemorrhoids)
  14. Unfit for pelvic MRI scanning (e.g., severe claustrophobia, permanent cardiac pacemaker, metallic implants that are likely to contribute significant image artifacts, allergy or contraindication to gadolinium (to enhance MRI)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01972867

Layout table for location information
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Angiodynamics, Inc.
Layout table for additonal information
Responsible Party: Angiodynamics, Inc.
ClinicalTrials.gov Identifier: NCT01972867    
Other Study ID Numbers: ON-NK310
First Posted: October 31, 2013    Key Record Dates
Last Update Posted: June 21, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Angiodynamics, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases